Concepedia

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus

Norman K. Hollenberg, Hans‐Henrik Parving, Giancarlo Viberti, Giuseppe Remuzzi, Susan Y. Ritter, Steven L. Zelenkofske, Albert Kandra, William Daley, Ricardo Rocha

Journal of Hypertension · 2007 · 145 citations · 7 references

DOI

Abstract

High doses of valsartan reduced albuminuria more than the more commonly used 160 mg dose, apparently independent of blood pressure. Thus, at least in type 2 diabetes mellitus, higher doses of valsartan are required to optimize tissue protection than for blood pressure control.

References

7

Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy

Dick de Zeeuw, Giuseppe Remuzzi, Hans‐Henrik Parving et al. · Circulation · 2004 · 749 citations

Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial

Marc A. Pohl, Samuel S. Blumenthal, D Cordonnier et al. · Journal of the American Society of Nephrology · 2005 · 373 citations

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

Kasper Rossing, K. J. Schjoedt, Berit R. Jensen et al. · Kidney International · 2005 · 226 citations

, , +8

Targeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade

Harm Peters, Wayne A. Border, Nancy A. Noble · Kidney International · 1998 · 222 citations · Full text

, , +11

Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan

Roland E. Schmieder, Arnfried U. Klingbeil, Erwin H. Fleischmann et al. · Journal of the American Society of Nephrology · 2005 · 151 citations

, , +14